{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"59"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"80"}],"units":"Participants"}],"description":"DCR = CR + PR + SD (Stable disease); IRC Evaluation DCR was defined as the number of participants having CR, PR or SD based on the best objective response achieved at any time during the study.","groups":[{"description":"MOR00208:\n\nMOR00208 was administered via IV infusion at a dose of 12 mg/kg. For the first three cycles (Cycles 1 to 3) of the study each cycle consisted of a MOR00208 infusion on Day 1, Day 8, Day 15 and Day 22 of the cycle.\n\nAdditionally, a loading dose was administered on Day 4 of Cycle 1. Thereafter MOR00208 was administered on a bi-weekly (every 14 days) basis with infusions on Day 1 and Day 15 of each 28-day cycle.\n\nLEN:\n\nParticipants self-administered a starting dose of 25 mg oral LEN daily on Days 1-21 of each cycle, for up to 12 cycles in total. LEN dose could be modified in a de-escalating fashion or discontinued based upon clinical and laboratory findings.\n\nOn days when both study drugs were given together, LEN was administered prior to MOR00208.","id":"OG000","title":"Tafasitamab (MOR00208) + Lenalidomide (LEN)"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"FAS: The FAS included all participants who received at least one dose of MOR00208 and at least one dose of LEN. This meant that both study drugs had to be administered at least once.","reportingStatus":"POSTED","timeFrame":"Approximately 2.5 years after first participant enrolled","title":"Disease Control Rate (DCR) by IRC Evaluation","type":"SECONDARY","unitOfMeasure":"Participants"}